                Figure 3.  Scintigraphic images of tumor-bearing mice 24 hours post-injection with: a) CasKi tumor, E6-specific mAb 188Re-C1P5 mAb; b) CasKi tumor, control 188Re-18B7 mAb; c) Hep 3B2.1-7 and A2058 human metastatic melanoma tumors, HBx-specific 188Re-4H9 mAb.
